Literature DB >> 6113145

Effects of intrinsic sympathetic activity of beta-blockers on SA and AV nodes in man.

J F Leclercq, M D Rosengarten, S Kural, P Attuel, P Coumel.   

Abstract

The authors compare the effects of beta-blockers without intrinsic sympathetic activity (ISA) (propranolol, 160 mg/day), moderate ISA (acebutolol, 800 mg/day) and high ISA (pindolol, 20 mg/day). The sinus rate decreases more with propranolol than with acebutolol, during the day (P less than 0.01) and during the night (P less than 0.001), whereas pindolol does not change the daylight rate and increases the nighttime rate (P less than 0.001). The ventricular rate during atrial fibrillation (AV nodal transmission) is modified as is sinus rate. There is no significant difference between propranolol and acebutolol, and a highly significant difference between pindolol and propranolol (P less than 0.001) or acebutolol (P less than 0.01). Moreover, the eurythmic effect of beta-blockers, making RR intervals more regular, is maximal with propranolol and minimal with pindolol, as judged on RR interval histograms. The ISA of the beta-blockers is of major importance for the clinical use of these drugs, and in the case of SA or AV node dysfunction ISA can be useful, but it can obscure the beneficial effects of beta-blocking therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113145

Source DB:  PubMed          Journal:  Eur J Cardiol        ISSN: 0301-4711


  3 in total

Review 1.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 2.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

3.  Electrophysiologic effects of intravenous xamoterol in patients with sinus node dysfunction.

Authors:  M de Marneffe; P Waterschoot; A Bernard; P Dubois; F Boujelben; I Liebens; M Englert
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.